Abstract

This study evaluated the bone regeneration capacity and mechanical properties of block-type hydroxyapatite (HA)/tricalcium phosphate (TCP) scaffolds in response to different concentrations of polydeoxyribonucleotide (PDRN) and recombinant human bone morphogenic protein 2 (rhBMP-2). Thirty-two male white rabbits were used as a model of calvarial bone defect and classified into eight groups according to type and concentration of growth factor administered, viz., control group (only HA/TCP scaffold), scaffold + PDRN (0.1, 1, 5, and 10 mg/mL each) and scaffold + rhBMP-2 (0.01, 0.05, and 0.1 mg/mL each). The specimens were evaluated using histomorphometric and radiological analyses. Histomorphometric analyses indicated that the administration of PDRN did not increase bone formation. However, significant increases in bone formation were observed with the administration of rhBMP-2 at 0.05 and 0.10 mg/mL on week 8 compared to the control (p < 0.05). Radiological analyses revealed a significant increase in bone formation at week 8 with the administration of PDRN at 5 mg/mL and 10 mg/mL, and rhBMP-2 at 0.05 or 0.10 mg/mL compared to the control (p < 0.05). Our findings show that block-type HA/TCP scaffolds possess sufficient mechanical strength and bone regeneration capacity when used with optimal concentrations of growth factors.

Highlights

  • Bone grafting in the oral and maxillofacial area to correct bony defects caused by pathology, trauma, or aging has been successful ­clinically[1]

  • A block-type scaffold composed of hydroxyapatite (HA) and tricalcium phosphate (TCP) was fabricated, and its mechanical strength was measured to investigate the clinical applicability of block-type ceramic scaffold grafts

  • The present study investigated bone regeneration using various concentrations of recombinant human bone morphogenic protein 2 (rhBMP-2) and PDRN in multiple specimens, their ability to increase bone formation may differ between animal and clinical studies due to the differences in body weight among s­ ubjects[45]

Read more

Summary

Introduction

Bone grafting in the oral and maxillofacial area to correct bony defects caused by pathology, trauma, or aging has been successful ­clinically[1]. The use of synthetic block-type bones that can replace autogenic block bone harvesting has limited clinical applications due to the lack of bone formation ability and the insufficient mechanical strength of large block ­sizes[8]. Bone morphogenic proteins (BMPs) are the most studied growth factors in bone r­ egeneration[11]; among them, recombinant human bone morphogenic protein 2 (rhBMP-2), which belongs to the transforming. Polydeoxyribonucleotide (PDRN) is a growth factor that has been studied in soft tissue healing and is effective in skin regeneration, angiogenesis, and wound ­repair[17,18]. Various concentrations of rhBMP-2 and PDRN were used to compensate for the insufficient bone-inducing ability of block-type ceramic scaffold grafts, and the optimal concentrations of rhBMP-2 and PDRN were determined to maximize new bone formation. The prospective significance of this study is to provide proper concentration of rhBMP-2 and PDRN for clinicians

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call